×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
复旦大学上海医学院 [6]
西安交通大学 [5]
中国医学科学院 北京... [5]
华南理工大学 [4]
新疆农业大学 [4]
昆明医科大学 [3]
更多...
内容类型
期刊论文 [28]
会议论文 [9]
发表日期
2019 [3]
2018 [15]
2016 [8]
2015 [2]
2014 [2]
2007 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共37条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
期刊论文
CANCER COMMUNICATIONS, 2019, 卷号: 39
作者:
Shi, Yuankai
;
Li, Jin
;
Xu, Jianming
;
Sun, Yan
;
Wang, Liwei
收藏
  |  
浏览/下载:113/0
  |  
提交时间:2019/12/05
CMAB009
Cetuximab
Irinotecan
Second-line
mCRC
EGFR
KRAS
Immunogenicity
Fluoropyrimidine
Oxaliplatin failure
Development and Validation of a Novel Signature to Predict Overall Survival in "Driver Genenegative" Lung Adenocarcinoma (LUAD): Results of a Multicenter Study
期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 5
作者:
Cui, Yongmei
;
Fang, Wenfeng
;
Li, Chaofeng
;
Tang, Kejing
;
Zhang, Jian
收藏
  |  
浏览/下载:37/0
  |  
提交时间:2019/12/05
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I
期刊论文
2019, 卷号: 39, 期号: 1, 页码: 28
作者:
Shi, Yuankai
;
Li, Jin
;
Xu, Jianming
;
Sun, Yan
;
Wang, Liwei
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2020/01/03
CMAB009
Cetuximab
Irinotecan
Second-line
mCRC
EGFR
KRAS
Immunogenicity
Fluoropyrimidine
Oxaliplatin failure
The age variation of HER2 immunohistochemistry positive rate in gastric cancer
期刊论文
LABORATORY INVESTIGATION, 2018, 卷号: 98
作者:
Xi, Yangfeng
;
Xu, Chen
;
Liu, Yiqiang
;
Yan, Xiaochu
;
Huang, Chuansheng
收藏
  |  
浏览/下载:47/0
  |  
提交时间:2019/12/04
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
;
Cheng, Ying
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/04
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Xiong, Jianping
;
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2019/12/05
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:
Ouyang, Xuenong
;
Shi, Meiqi
;
Jie, Fangwei
;
Bai, Yuxian
;
Shen, Peng
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2019/12/05
Phase III
Dulanermin
NSCLC
Progression-free survival
Objective response rate
The age variation of HER2 immunohistochemistry positive rate in gastric cancer
会议论文
作者:
Qin, Yejun
;
Liu, Jianping
;
Li, Daiqiang
;
Wang, Guoping
;
Nie, Xiu
收藏
  |  
浏览/下载:39/0
  |  
提交时间:2019/12/05
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
;
Cheng, Ying
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/05
The age variation of HER2 immunohistochemistry positive rate in gastric cancer
会议论文
作者:
Xi, Yangfeng
;
Xu, Chen
;
Liu, Yiqiang
;
Yan, Xiaochu
;
Huang, Chuansheng
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2019/12/05
©版权所有 ©2017 CSpace - Powered by
CSpace